NCT02834741View on ClinicalTrials.gov

Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

NYX-2925

NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.

Trial Locations (1)

53095

Spaulding Clinical, West Bend

Sponsors

Lead Sponsor

Aptinyx
All Listed Sponsors
collaborator

Spaulding Clinical Research LLC

OTHER

lead

Aptinyx

INDUSTRY

NCT02834741 - Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers | Biotech Hunter | Biotech Hunter